Arbutus Biopharma Corporation ABUS Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions
Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's debt securities, available-for-sale, unrealized loss position, number of positions.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's debt securities, available-for-sale, unrealized loss position, number of positions?
- Arbutus Biopharma Corporation (ABUS) reported debt securities, available-for-sale, unrealized loss position, number of positions of $22 in Q1 2026.
- How has Arbutus Biopharma Corporation's debt securities, available-for-sale, unrealized loss position, number of positions changed year-over-year?
- Arbutus Biopharma Corporation's debt securities, available-for-sale, unrealized loss position, number of positions increased by 57.1% year-over-year, from $14 to $22.
- What is the long-term trend for Arbutus Biopharma Corporation's debt securities, available-for-sale, unrealized loss position, number of positions?
- Over 3 years (2022 to 2025), Arbutus Biopharma Corporation's debt securities, available-for-sale, unrealized loss position, number of positions has grown at a -100.0% compound annual growth rate (CAGR), from $53 to $0.